Mercado Global de Medicamentos para Doenças Cardiovasculares – Tendências da Indústria e Previsão para 2029

Análise e dimensão do mercado de medicamentos para doenças cardiovasculares

Espera-se que o mercado global de medicamentos para doenças cardiovasculares testemunhe um enorme crescimento no período de previsão. O aumento dos casos de hipertensão e outras doenças cardiovasculares impulsiona o mercado dos betabloqueantes não cardiosseletivos. É utilizado para prevenir ou melhorar os sintomas em pessoas com ritmo cardíaco anormal, dor no peito, ataques cardíacos, insuficiência cardíaca, enxaqueca e tipos de tremores. O COVID-19 também teve um grande impacto no crescimento do mercado.

A Data Bridge Market Research analisa uma taxa de crescimento no mercado global de medicamentos para doenças cardiovasculares no período de previsão 2022-2029. O CAGR esperado do mercado global de medicamentos para doenças cardiovasculares tende a rondar os 5,02% no período de previsão mencionado. O mercado foi avaliado em 155,6 milhões de dólares em 2021 e cresceria até 230,24 milhões de dólares até 2029. Para além dos insights de mercado, como o valor de mercado, taxa de crescimento, segmentos de mercado, cobertura geográfica, participantes no mercado e cenário de mercado, o O relatório de mercado com curadoria da equipa de pesquisa de mercado da Data Bridge inclui também uma análise especializada aprofundada, epidemiologia dos doentes, análise de pipeline, análise de preços e estrutura regulamentar.

Âmbito e segmentação do mercado de medicamentos para doenças cardiovasculares

Market Definition

The disorders or conditions affecting the structures and function of the heart and blood vessels are known as cardiovascular diseases. Cardiovascular disease is recognized as one of the major top cause of global death. It is generally a prolonged condition and affects mainly the elderly population. Cardiovascular drugs cannot be discontinued easily by a patient as it requires a proper judgment of the patient's cardiac health that may prove to be fatal in the long run.  

Global Cardiovascular Disease Drug Market Dynamics

Drivers

• Increase in Cardiovascular Diseases

According to the WHO, around 60% - 85% of the population have adopted a sedentary life. According to CDC, approximately 31 million adults aged over 50 years live a sedentary life, and only 1 out of 4 U.S. adults meet the appropriate need of physical activity. This boost the market growth.

• Rising FDA Approvals

The persistent product approvals are expected to drive the market growth. For instance, in May 2022, Zydus Lifesciences Limited’s subsidiary, received tentative approval from the U.S. FDA to market Selexipag tablets that is used to treat pulmonary arterial hypertension (PAH) in adults. In addition, in February 2022, the FDA approved the Norliqva (amlodipine) oral solution to treat hypertension in adults and children 6 years or older, to lower blood pressure and coronary artery disease.

Opportunities

• Rising Prevalence of Hypertension

As per the American College of Cardiology, older adults are mostly undertreated for high blood pressure, despite having the maximum prevalence of hypertension and the highest risk of CV morbidity and mortality (BP). According to the National Health and Nutrition Examination Survey (NHANES) records in the U.S., hypertension affects 70% of persons over 65 years. As our population ages, this figure will continue to rise. In 2014, 15% of the US population was 65 years old, and that number is projected to rise to 20% by 2050. This will create more opportunities for the market growth as the demand for blockers also increases.

• Increasing Demand for Retail Pharmacies

The rise in the number of cardiovascular disease drug delivered through retail pharmacies and the rise in the number of retail pharmacies in highly developed countries can create opportunities for the market growth. Additionally, patients prefer retail pharmacies for purchasing drugs, as these are easily accessible.

 Restraints/Challenges

• Lack of skilled professionals

The lack of qualified healthcare professionals who cannot treat the patients with these agents could impede the growth of the global cardiovascular disease drug market over a forecast period.

• Side Effects of Cardioselective Beta Blockers

There are various side effects associated with cardiovascular disease drug such as upset stomach, nausea, diarrhea or constipation, and erectile dysfunction when taking beta-blockers that hamper the market growth.

This global cardiovascular disease drug market report provides details of new recent developments, trade regulations, import-export analysis, production analysis, value chain optimization, market share, impact of domestic and localized market players, analyses opportunities in terms of emerging revenue pockets, changes in market regulations, strategic market growth analysis, market size, category market growths, application niches and dominance, product approvals, product launches, geographic expansions, technological innovations in the market. To gain more info on the global cardioselective beta blockers market contact Data Bridge Market Research for an Analyst Brief, our team will help you take an informed market decision to achieve market growth.

COVID-19 Impact on Global Cardiovascular Disease Drug Market            

The COVID-19 pandemic faced moderately great impact on the market growth. Hypertension is one of the most common phenomenon in COVID-19 patients; thus, beta-blockers are widely used. In addition to this, the pandemic is interrupting the medical supply chain, and the delivery of the prooducts. The COVID-19 pandemic affected healthcare systems worldwide and interrupted usual care in many healthcare facilities, exposing vulnerable patients with cardiovascular diseases to significant risks. Though, the demand for cardiovascular drugs increased during the pandemic due to the increased risk of infection among patients with cardiovascular diseases (CVDs). But in the post pandemic era, the market is rising as the hospitals and clinics are free from the tedious responsibilities of COVID-19 patients.Thus, the market will undergo growth during the forecast period.

Recent Developments:

• In May 2022, Amgen revealed positive data from the Phase 2 OCEAN(a)-DOSE clinical study, evaluating olpasiran in 281 adult patients with Lipoprotein(a), or Lp(a), levels over 150 nmol/L and evidence of atherosclerotic cardiovascular disease (ASCVD). Olpasiran is a small interfering RNA designed to lower the body's production of apolipoprotein(a), a key component of Lp(a) associated with an increased risk of cardiovascular events.

Global Cardiovascular Disease Drug Market Scope

The global cardiovascular disease drug market is segmented on the basis of diseases, treatment, route of administration, distribution channel and end-user. The growth amongst these segments will help you analyze meagre growth segments in the industries and provide the users with a valuable market overview and market insights to help them make strategic decisions for identifying core market applications.

Diseases

• Hypertension
• Dyslipidemia
• Inflammatory Heart Disease
• Ischemic Heart Disease
• Others

Treatment

• Antiplatelet, Agents
• Beta-Blockers
•  Angiotensin-Converting Enzyme Inhibitors
• Others

Route of Administration

• Oral
• Parenteral
• Others

End User

• Hospitals
• Homecare
• Specialty Clinics
• Others

Distribution Channel

• Hospital Pharmacy
• Online Pharmacy
• Retail Pharmacy

Cardiovascular Disease Drug Market Regional Analysis/Insights

The global cardiovascular disease drug market is analyzed and market size insights and trends are provided by diseases, treatment, route of administration, distribution channel and end-user as referenced above.

The major countries covered in the global cardiovascular disease drug market report are the U.S., Canada and Mexico in North America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC) in the Asia-Pacific (APAC), Saudi Arabia, U.A.E, South Africa, Egypt, Israel, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA), Brazil, Argentina and Rest of South America as part of South America.

North America has been witnessing a positive growth for global cardiovascular disease drug market throughout the forecasted period due to the global leaders in research and development activities, high incidence of heart diseases and presence of refined medical facilities.

Asia-Pacific dominates the market due to the developing healthcare facilities, large number of generic manufacturer and rise in government initiatives and specialist communities.

The country section of the report also provides individual market impacting factors and changes in regulation in the market domestically that impacts the current and future trends of the market. Also, the presence and availability of global brands and their challenges faced due to large or scarce competition from local and domestic brands, impact of domestic tariffs and trade routes are considered while providing forecast analysis of the country data.   

Competitive Landscape and Global Cardiovascular Disease Drug Market Share Analysis

O panorama competitivo do mercado global de medicamentos para doenças cardiovasculares fornece detalhes por concorrente. Os detalhes incluídos são a visão geral da empresa, finanças da empresa, receitas geradas, potencial de mercado, investimento em investigação e desenvolvimento, novas iniciativas de mercado, presença global, localizações e instalações de produção, capacidades de produção, pontos fortes e fracos da empresa , lançamento de produto, largura e amplitude do produto, aplicação domínio. Os dados acima fornecidos estão apenas relacionados com o foco das empresas relacionado com o mercado global de medicamentos para doenças cardiovasculares

Os principais players que trabalham no mercado global de medicamentos para doenças cardiovasculares incluem:

• F. Hoffmann-La Roche Ltd (Suíça)
• Fresenius Kabi AG (Alemanha)
• Bayer AG (Alemanha)
• Sun Pharmaceutical Industries Ltd (Índia)
• Novartis AG (Suíça)
• Mylan NV (EUA)
• Teva Pharmaceutical Industries Ltd (Israel)
• Grupo Zydus (Índia)
• Pfizer Inc (EUA)
• Lupin (Índia)
• GSK Plc (Reino Unido)
• Glenmark Pharmaceuticals Inc (Índia)
• Capricor Therapeutics (EUA)
• Zensun (China)

SKU-54687